Biogen and Denali halt development of Parkinson's therapy Biogen and Denali Therapeutics have decided to discontinue the development of an experimental therapy for Parkinson's disease. The decision comes after a mid-stage trial setback. The companies' shares fell
Biogen and Denali halt development of Parkinson’s therapy
Biogen and Denali Therapeutics have decided to discontinue the development of an experimental therapy for Parkinson’s disease.
The decision comes after a mid-stage trial setback.
The companies’ shares fell in premarket trading on Friday following the announcement.
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.
